Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the … Read more
Vericel Corporation (ATQP) - Total Liabilities
Latest total liabilities as of September 2025: €131.42 Million EUR
Based on the latest financial reports, Vericel Corporation (ATQP) has total liabilities worth €131.42 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vericel Corporation - Total Liabilities Trend (2014–2024)
This chart illustrates how Vericel Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Vericel Corporation Competitors by Total Liabilities
The table below lists competitors of Vericel Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
American Superconductor Corporation
NASDAQ:AMSC
|
USA | $182.70 Million |
|
Fujian Huoju Electronic
SHG:603678
|
China | CN¥2.10 Billion |
|
Nektar Therapeutics
NASDAQ:NKTR
|
USA | $216.26 Million |
|
Jiangsu Dingsheng New Material Joint-Stock Co Ltd
SHG:603876
|
China | CN¥17.69 Billion |
|
JUSUNG ENGINEERING Co. Ltd
KQ:036930
|
Korea | ₩278.20 Billion |
|
Columbia Sportswear Company
NASDAQ:COLM
|
USA | $1.22 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Vericel Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vericel Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vericel Corporation (2014–2024)
The table below shows the annual total liabilities of Vericel Corporation from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €140.75 Million | +10.22% |
| 2023-12-31 | €127.70 Million | +58.19% |
| 2022-12-31 | €80.73 Million | +10.22% |
| 2021-12-31 | €73.24 Million | +2.66% |
| 2020-12-31 | €71.35 Million | +69.28% |
| 2019-12-31 | €42.15 Million | +156.09% |
| 2018-12-31 | €16.46 Million | -48.63% |
| 2017-12-31 | €32.04 Million | +34.10% |
| 2016-12-31 | €23.89 Million | +96.16% |
| 2015-12-31 | €12.18 Million | +2.02% |
| 2014-12-31 | €11.94 Million | -- |